Company overview
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Daily valuation snapshot
These values are from the stored daily market snapshot dated 2026-10-08. They are not a live quote.
| Daily close (USD) | $2.02 |
| Market capitalization (USD) | $79,687,921.32 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.34 |
No matching rows. Clear the filter to see all records.
Continue the research
Read public ownership disclosures separately from company fundamentals. Test a strategy against dated historical observations before evaluating its assumptions; a past result is not a live trading outcome.